In Vitro Evaluation of Astaxanthin-Loaded Fetal Bovine Serum-Derived Extracellular Vesicles in MCF-7 Breast Cancer Cells
Pharmedicine Journal · 2026-10-31 · 3 (3) · 72-81
DOI: 10.62482/pmj.72 ↗Abstract
Introduction: Current cancer treatment has significant limitations such as severe side effects, low cell selectivity and the development of drug resistance. Therefore, the investigation of alternative treatments derived from natural sources is required. Although astaxanthin exhibits anticancer property, its low solubility and stability presents formulation challenges. Extracellular vesicles have emerged as potential carriers for bioactive compounds. This study aims to investigate Astaxanthin esters (AXT)-incubated EVs derived from fetal bovine serum (FBS) and evaluate their effects on cell viability, wound closure and oxidative balance in MCF-7 breast cancer cells. Methods: FBS-derived EVs were isolated by ultracentrifugation, characterized and loaded with AXT through incubation. MCF-7 cells were treated with AXT, EVs and AXT-EVs. Cell viability, oxidative balance and wound closure were assessed using MTT, TAS/TOS and wound healing assays, respectively. Results: AXT reduced MCF-7 cell viability in a concentration-dependent manner, whereas EVs and AXT-EVs showed limited effects on cell viability at the tested concentrations. All kinds of treatment reduced wound closure at 24 and 48 hours, with EVs showing the greatest reduction. AXT-EVs also decreased TOS levels, indicating changes in oxidative balance. Conclusions: This study provides preliminary in vitro evidence of changes in cell viability, wound closure and oxidative balance following treatment with AXT, FBS-derived EVs and AXT-EVs in MCF-7 cells. Further studies are required to clarify the contribution of AXT loading and the mechanisms underlying the observed cellular responses.
EUVIMED